Genes Dysregulated in Autism as Potential Biomarkers and Therapeutic Targets
University of California System: University of California, Los Angeles - UCLA
posted on 05/02/2012
Brief description unavailable
- Identifies a cohort of gene expression changes in the disease-relevant tissue (ASD brain).
- Can be used as genetic biomarkers for the accurate and early diagnosis of ASD in young children.
- Describes the dysregulated molecular pathways that may include candidates for preventive approaches or treatment therapeutics for ASD patients.
- Some of the gene changes are also seen in peripheral blood lymphocytes, indicating that they may serve as biomarkers for ASD diagnosis.
Researchers at UCLA have characterized the genome-wide expression profiles of postmortem brain tissue from several brain regions in ASD patients and controls. They identified numerous genes showing consistent changes in expression level and employed a network-based approach to identify groups of functionally-related genes that are aberrantly expressed in the ASD brain. These analyses highlight genes that are dysregulated in ASD in the disease-relevant tissue, and define a set of co-expressed genes that may serve as therapeutic candidates or potential biomarkers for the disease. Some of the identified genes also change in peripheral blood lymphocytes, suggesting that these genes may serve as diagnostic biomarkers in peripheral tissue samples. The molecular entities identified herein can be utilized as a genetic diagnostic test for ASD, or exploited for the discovery and development of ASD therapeutics.
File Number: 22469
Disease: Central Nervous System
|Copyright:||©2012-2013, The Regents of the University of California|
This innovation currently is not available for online licensing. Please contact UCLA Office of Intellectual Property & Industry Sponsored Research at University of California System: University of California, Los Angeles - UCLA for more information.request more info
Find more innovations